BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Closed|| Long (1Y)
Macquarie maintains outperform on Glenmark Pharmaceuticals
Trading multiple re-rating likely for the stock. Current valuations look attractive. The stock is trading at a multiple of around 13 times to its FY18 estimated earnings. Current weakness is an opportunity for investors.